Monoclonal antibodies

#Addiction #Antibodies #Cessation Therapeutics #Drug abuse #Monoclonal antibodies #Opioids #Overdose

Can an antibody therapy prevent fentanyl overdoses?

DDW Editor Reece Armstrong speaks to Tracy M Woody, President and Chief Executive Officer of Cessation Therapeutics, about the company’s goal to develop an antibody therapy to prevent fentanyl overdoses. Cessation Therapeutics is a pharmaceutical company that is developing antibody therapies to prevent and reverse overdosing caused by fentanyl. Recently,… Read More

#Exclusive Content

Monoclonal antibodies
#Antibodies #Bioproduction #Monoclonal antibodies #Tokyo University of Science

Researchers from Japan take a new approach to enhancing antibodies

Researchers from Tokyo University of Science (TUS) have found a simple, low-cost way to optimise the production of monoclonal antibodies (mAbs) and reduce manufacturing costs. Dr Kyohei Higashi, Associate Professor at TUS, along with a team of researchers, conducted a study to explore the effects of… Read More

#News

#Arxx Therapeutic #Calluna Pharma #Funding #Immune system #Monoclonal antibodies #Oxitope Pharm #Therapeutic Antibodies

Calluna Pharma announces €75 million Series A financing 

Oxitope Pharma and Arxx Therapeutics, companies with a shared goal of leveraging the innate immune system to discover and develop disease modulating therapies, has announced their merger to form Calluna Pharma.   Calluna has raised €75 million in a series A financing and is backed by Oxitope and Arxx’s existing… Read More

#Business & Investment #News

#CAR-T #FDA #MHRA #Monoclonal antibodies #NMPA #Oncology #Regulatory

New DDW Highlights podcast: 15 January 2024

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  This week has seen a number of significant discoveries by researchers in academic institutions,… Read More

#News

#CAR-T #FDA #MHRA #Monoclonal antibodies #NMPA #Oncology #Regulatory

This week in drug discovery (8-12 January) 

News round-up for 8-12 January by DDW Digital Content Editor Diana Spencer. This week has seen a number of significant discoveries by researchers in academic institutions, in some cases in partnership with industry, emphasising the important role universities play in early-stage drug discovery. Perhaps most importantly,… Read More

#News

GSK offices
#Asthma #GSK #Mergers and acquisitions #Monoclonal antibodies #Respiratory

GSK expands respiratory pipeline with Aiolos Bio acquisition

GSK is to acquire Aiolos Bio for a $1 billion upfront payment and up to $400 million in regulatory milestone payments. The acquisition includes Aiolos’ AIO-001, a potentially best-in-class, long-acting anti-thymic stromal lymphopoietin (TSLP) monoclonal antibody ready to enter Phase II clinical development for asthma, with potential for additional indications. Read More

#Business & Investment #News

#CAR-T #FDA #MHRA #Monoclonal antibodies #NMPA #Oncology #Regulatory

New DDW Highlights podcast for 8 January 2024

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  The start of 2024 has seen quite a bit of regulatory activity, with the… Read More

#News

#CAR-T #FDA #MHRA #Monoclonal antibodies #NMPA #Oncology #Regulatory

This week in drug discovery (1-5 January) 

News round-up for 1-5 January by DDW Digital Content Editor Diana Spencer. The start of 2024 has seen quite a bit of regulatory activity, with the UK MHRA’s launch of a new procedure for assessing drugs, along with significant regulatory approvals for therapeutics for cytomegalovirus, melanoma,… Read More

#News

Monoclonal antibody
#Bristol Myers Squibb #Melanoma #MHRA #Monoclonal antibodies #Project Orbis

Nivolumab-relatlimab combination for melanoma approved in UK

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved Bristol Myers Squibb’s advanced melanoma drug Opdualag (nivolumab-relatlimab) for patients from the age of 12. Opdualag was authorised through Project Orbis, a global partnership between the MHRA, the Therapeutics Goods Administration in Australia, Health Canada, the Health Sciences Authority… Read More

#News #Regulatory

Monoclonal antibodies
#Anti-inflammatory #Financing #Lassen Therapeutics #Monoclonal antibodies #Ophthalmology

$85m fund supports monoclonal antibody for fibro-inflammatory disorders

Antibody therapeutics company Lassen Therapeutics has closed an oversubscribed $85 million Series B financing. The proceeds will fund a Phase II study in thyroid eye disease (TED) with the company’s monoclonal antibody LASN01 and the continued development of LASN500 for cancer. The clinical programme for LASN01 is focused primarily in… Read More

#Business & Investment #News

Therapeutic antibodies
#Antibodies #Engineered antibodies #Immunology #Janssen #Monoclonal antibodies

Finding the North Star of therapeutic antibodies

Listen to this article on the DDW Podcast: Katie Abouzahr is the Vice President, Autoantibody Portfolio and Maternal Fetal Disease Area Leader at the Janssen Pharmaceutical Companies of Johnson & Johnson. She speaks with Megan Thomas about the future for Janssen’s investigational medicine nipocalimab and antibody therapeutics at large. A day in… Read More

#Exclusive Content

HIV test
#FDA #HIV #Monoclonal antibodies #Theratechnologies

Results from HIV mAB intramuscular administration study 

Theratechnologies, a biopharmaceutical company focused on the development and commercialisation of innovative therapies, has announced results from a study evaluating an intramuscular (IM) method of administration for Trogarzo (ibalizumab-uiyk), a monoclonal antibody antiretroviral therapy (ART) for the treatment of heavily treatment-experienced adults with multidrug-resistant (MDR) HIV-1 infection failing their… Read More

#News

IgG1 monoclonal antibody
#Artificial intelligence (AI) #Aulos Bioscience #Monoclonal antibodies #Oncology #Phase I trial #Solid tumours

Data supports IgG1 monoclonal antibody for solid tumours

Aulos Bioscience has revealed new safety and efficacy data from the Phase I dose escalation portion of its Phase I/II clinical trial of AU-007 in patients with unresectable locally advanced or metastatic solid tumour cancers. The data will be presented at the Society for Immunotherapy of… Read More

#Cancer Research #News

#Antibodies #Antibody drug conjugate (ADC) #CAR-T #Drug development #Drug discovery #Immunotherapy #Monoclonal antibodies

New DDW Highlights podcast: 2 October 2023

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  Immunotherapy has taken centre stage this week, with several announcements relating to… Read More

#News

#Antibodies #Antibody drug conjugate (ADC) #CAR-T #Drug development #Drug discovery #Immunotherapy #Monoclonal antibodies

This week in drug discovery (25-29 September)  

News round-up for 25-29 September by DDW Digital Content Editor Diana Spencer. Immunotherapy has taken centre stage this week, with several announcements relating to regulatory approval, investment and research results for antibody and CAR-T therapies, perhaps most significantly, encouraging early-stage data for the first in vivo… Read More

#News

Monoclonal antibodies
#AbolerIS Pharma #Arthritis #Autoimmune disease #Financing #Monoclonal antibodies

€27.3M to advance monoclonal antibody for autoimmune diseases

AbolerIS Pharma has raised €27.3 million in a Series A financing led by Caixa Capital Risc and co-led by Sound Bioventures and Newton Biocapital. Proceeds from the financing will enable AbolerIS to accelerate the development of its lead programme in clinical trials and explore its effectiveness in additional autoimmune diseases. Read More

#Business & Investment #News